Navigation Links
Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
Date:8/13/2009

VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced that it has received approval to begin marketing the Quill(TM) SRS Polydioxanone (PDO), MONODERM(TM), Polypropylene and Nylon product lines in Brazil.

"We are very excited about the approval of the Quill SRS product lines in Brazil, one of the largest surgical markets in the world. Quill has been lauded in the U.S., Europe and Canada for the efficiency it brings to wound closure. Now, Brazilian patients and surgeons in plastics, orthopedics and gynecology can benefit from it as well," said Dr. William Hunter, President and CEO of Angiotech.

The Quill SRS product lines include two absorbable sutures - MONODERM and PDO, and two non-absorbable sutures - Polypropylene and Nylon, and are approved for sale in the U.S., Europe, and Canada.

About the Quill(TM) Self-Retaining System (SRS)

Quill SRS represents a revolutionary technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill SRS distribute tension across the wound and eliminate the need for knots.

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Ca
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Feb. 13 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... 2008. The net loss for the second quarter of fiscal ... net loss of $5.9 million,or $0.23 per share, in the ... Total operating expenses were $4.9 million in the second quarter ...
... China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC ... manufacturer and distributor of high-quality, pharmaceutical grade,glucose products ... second,quarter of fiscal 2009 ended December 31, 2008. ... glucose products increased during the second quarter,compared with ...
... Creation Best Practice Findings to be released at SiriusDecisions B-to-B ... ... February 13, 2009 -- SiriusDecisions, the world,s leading source for ... announced that top executives from Hewlett-Packard Company, IBM Corporation and ...
Cached Biology Technology:Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 7Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 2Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 3Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 4Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 5Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 6Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 7Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 8Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 9Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 10Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 11Senior Executives from HP, IBM and Omniture Headline "Leaders and Lessons Learned" Sales and Marketing Summit 2009 2Senior Executives from HP, IBM and Omniture Headline "Leaders and Lessons Learned" Sales and Marketing Summit 2009 3
(Date:7/11/2014)... creating a new professorship in tissue engineering to ... Molecular Engineering and the Marine Biological Laboratory, supported ... and Eugene Bell Foundation., The Eugene Bell Professorship ... for Molecular Engineering. That endowed chair holder also ... Eugene Bell Center for Regenerative Biology and Tissue ...
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2Molecular snapshots of oxygen formation in photosynthesis 2
... of Warwick are examining a way of using bacteria ... that are difficult to create synthetically on a lab ... called prodiginines. , This group of antibiotics has ... to target and kill cancer cells. A synthetic prodiginine ...
... newly created by the University of California, Berkeley, and Lawrence ... the body's cells that can be flipped on and off ... Optical switches like these could trigger a chemical reaction, initiate ... cell - all at the flash of a light. ...
... engineers have developed a computer tool they say could ... women to use to prevent infection by the virus ... is a pressing challenge because women now account for ... said. , By applying fundamentals of physics and chemistry, ...
Cached Biology News:Light-sensitive photoswitches could restore sight to those with macular degeneration 2Light-sensitive photoswitches could restore sight to those with macular degeneration 3Study defines effective microbicide design for HIV/AIDS prevention 2Study defines effective microbicide design for HIV/AIDS prevention 3
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Pendrin (H-195)...
Biology Products: